Please select the option that best describes you:
How do you decide between abiraterone or docetaxel for first line treatment of newly diagnosed metastatic prostate cancer?
Given that ADT + abiraterone and ADT + docetaxel have not been directly compared.
Answer from: Medical Oncologist at Academic Institution
Abiraterone (LATITUDE and STAMPEDE trials) and docetaxel (CHAARTED and STAMPEDE trials) both have level 1 evidence supporting their use in men with metastatic hormone-sensitive prostate cancer. However, a pre-planned subset analysis from the CHAARTED study demonstrated that docetaxel only appeared t...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
I agree and would only point out that a recent analysis of docetaxel/ADT outcomes in STAMPEDE by disease volume, have identified improved overall survival regardless of disease volume. In this 2019 ESMO late-breaking abstract, which is still not published to my knowledge, the HR for OS in high volum...